Follow-up of monotherapy remitters in the PReDICT study: Maintenance treatment outcomes and clinical predictors of recurrence.
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study followed remitted patients from a randomized controlled trial of adults with major depressive disorder (MDD). The aims were to describe rates of recurrence and to evaluate 3 clinical predictor domains. METHOD: Ninety-four treatment-naïve patients (50% female; Mage = 38.1 years; 48.9% White; 30.9% Hispanic) with MDD who had remitted to 12-week monotherapy (escitalopram, duloxetine, or cognitive behavior therapy [CBT]) participated in a 21-month maintenance phase (i.e., continued medication or 3 possible CBT booster sessions per year). Recurrence was assessed quarterly, and the clinical predictors were the following: 2 measures of residual depressive symptoms, 1 measure of lifetime depressive episodes, and 2 measures of baseline anxiety. Survival analysis models evaluated recurrence rates, and regression models evaluated the predictors. RESULTS: Among all patients, 15.5% experienced a recurrence, and the survival distributions did not statistically differ among treatments. Residual depressive symptoms on the Hamilton Depression Rating Scale at the end of monotherapy were associated with increased risk for recurrence (hazard ratio = 1.31, 95% confidence interval [CI: 1.02, 1.67], Wald χ2 = 4.41, p = .036), and not having a comorbid anxiety disorder diagnosis at study baseline reduced the risk of recurrence (hazard ratio = .31, 95% CI [.10, .94], Wald χ2 = 4.28, p = .039). CONCLUSIONS: The study supported the benefits of maintenance treatment for treatment-naïve patients who remitted to initial monotherapy; nevertheless, remitted patients with a comorbid anxiety disorder diagnosis at the beginning of treatment or residual depressive symptoms after initial treatment were at risk for poorer long-term outcomes. (PsycINFO Database Record
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., et al. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.4.658 · Cited by 1,607
Toward a unified treatment for emotional disorders
Barlow, D. H., Allen, L. B., & Choate, M. L. (2004) · Behavior Therapy · doi:10.1016/s0005-7894(04)80036-4 · Cited by 1,430
Keller, M. B., McCullough, J. P., Klein, D. N., Arnow, B., Dunner, D. L., Gelenberg, A. J., Markowitz, J. C., Nemeroff, C. B., Russell, J. M., Thase, M. E., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422001 · Cited by 1,331 · cited 1×
“This finding has important implications for treatment because many patients end initial treatment with residual symptoms (DeRubeis et al., 2005; Dimidjian et al., 2006; Dunlop et al., 2017; Elkin et al., 1989; Keller et al., 2000).”
Self-citationMaier, W., Buller, R., Philipp, M., & Heuser, I. (1988) · Journal of Affective Disorders · doi:10.1016/0165-0327(88)90072-9 · Cited by 1,044
Risk for recurrence in depression
Burcusa, S. L., & Iacono, W. G. (2007) · Clinical Psychology Review · doi:10.1016/j.cpr.2007.02.005 · Cited by 1,023
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 5×
“The overall recurrence rate of 15.5% was lower than the rates reported for patients followed naturalistically (e.g., Solomon et al., 2000) and for patients who responded to initial ADM treatment and then switched to placebo (Borges et al., 2014; Geddes et al., 2003; Glue et al., 2010).”
InfluentialRecurrence after recovery from major depressive disorder during 15 years of observational follow-up
Mueller, T. I., Leon, A. C., Keller, M. B., Solomon, D. A., Endicott, J., Coryell, W., Warshaw, M., & Maser, J. D. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1000 · Cited by 897 · cited 2×
“…found that patients with more lifetime depressive episodes are at increased risk of recurrence (e.g., Bulloch, Williams, Lavorato, & Patten, 2014; Mueller et al., 1999), and lifetime MDEs have been found to moderate treatment outcomes to psychotherapies that specifically target the prevention of…”
Multiple recurrences of major depressive disorder
Solomon, D. A., Keller, M. B., Leon, A. C., Mueller, T. I., Lavori, P. W., Shea, M. T., Coryell, W., Warshaw, M., Turvey, C., Maser, J. D., et al. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.229 · Cited by 835 · cited 5×
“The overall recurrence rate of 15.5% was lower than the rates reported for patients followed naturalistically (e.g., Solomon et al., 2000) and for patients who responded to initial ADM treatment and then switched to placebo (Borges et al., 2014; Geddes et al., 2003; Glue et al., 2010).”
InfluentialKuyken, W., Warren, F. C., Taylor, R. S., Whalley, B., Crane, C., Bondolfi, G., Hayes, R., Huijbers, M., Ma, H., Schweizer, S., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0076 · Cited by 821
Residual symptoms after partial remission: an important outcome in depression
Paykel, E. S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., & Barocka, A. (1995) · Psychological Medicine · doi:10.1017/s0033291700033146 · Cited by 791 · cited 4×
“This finding is consistent with the aforementioned evidence for residual symptoms’ predicting relapse and recurrence (Judd et al., 1998; Paykel et al., 1995) and with STAR D findings that residual symptoms predicted relapse among remitters to initial treatment (Nierenberg et al.”
InfluentialJudd, L. L., Akiskal, H. S., Maser, J. D., Zeller, P. J., Endicott, J., Coryell, W., Paulus, M. P., Kunovac, J. L., Leon, A. C., Mueller, T. I., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.8.694 · Cited by 775
Prevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735 · cited 5×
“Further, because of appropriate a priori research design reasons, the few studies that have directly compared the long-term efficacy of CBT and continuation ADMs for longer than 1 year of follow-up have, at the end of 1 year of treatment, withdrawn continuation ADM patients from treatment rather than maintaining them…”
InfluentialNational Patterns in Antidepressant Medication Treatment
Olfson, M., & Marcus, S. C. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.81 · Cited by 730 · cited 14×
“Moreover, evidence that residual symptoms predict recurrence even among remitters has supported recent efforts to define more stringent MDD outcome criteria (Dunlop, Holland, Bao, Ninan, & Keller, 2012; Judd et al., 2016).”
InfluentialDobson, K. S., Hollon, S. D., Dimidjian, S., Schmaling, K. B., Kohlenberg, R. J., Gallop, R. J., Rizvi, S. L., Gollan, J. K., Dunner, D. L., & Jacobson, N. S. (2008) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.76.3.468 · Cited by 560
Toward a unified treatment for emotional disorders - republished Article
Barlow, D. H., Allen, L. B., & Choate, M. L. (2016) · Behavior Therapy · doi:10.1016/j.beth.2016.11.005 · Cited by 536
Prevalence and predictors of recurrence of major depressive disorder in the adult population
Hardeveld, F., Spijker, J., De Graaf, R., Nolen, W. A., & Beekman, A. T. F. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01519.x · Cited by 486
Enduring Effects for Cognitive Behavior Therapy in the Treatment of Depression and Anxiety
Hollon, S. D., Stewart, M. O., & Strunk, D. (2006) · Annual Review of Psychology · doi:10.1146/annurev.psych.57.102904.190044 · Cited by 466
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388 · cited 1×
“It provides much-needed long-term follow-up information regarding the comparable efficacy of CBT and ADMs and supports recommendations to make full remission the target of initial treatment (Keller, 2003).”
Cuijpers, P., Hollon, S. D., van Straten, A., Bockting, C., Berking, M., & Andersson, G. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002542 · Cited by 253 · cited 15×
“Cognitive behavioral therapy (CBT), an evidence-based psychotherapy and alternative first-line treatment approach to ADMs, also appears to reduce the risk of relapse and recurrence.”
InfluentialBockting, C. L. H., DELTA Study Group, Schene, A. H., Spinhoven, P., Koeter, M. W. J., Wouters, L. F., Huyser, J., & Kamphuis, J. H. (2005) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.73.4.647 · Cited by 249 · cited 1×
“…of recurrence (e.g., Bulloch, Williams, Lavorato, & Patten, 2014; Mueller et al., 1999), and lifetime MDEs have been found to moderate treatment outcomes to psychotherapies that specifically target the prevention of MDD relapse and recurrence (e.g., Bockting et al., 2005; Teasdale et al., 2000).”
Stangier, U., Hilling, C., Heidenreich, T., Risch, A. K., Barocka, A., Schlösser, R., Kronfeld, K., Ruckes, C., Berger, H., Röschke, J., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060734 · Cited by 174 · cited 1×
“…there is evidence that MDD becomes a chronic, recurrent disorder after three lifetime episodes (Solomon et al., 2000), and this dichotomous classification has been employed in many studies of recurrence of major depression (Craighead & Dunlop, 2014; Kuyken et al., 2016; Stangier et al., 2013).”
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158 · cited 1×
“…the low level of residual depressive symptoms due to all included patients’ having achieved remission during the acute treatment phase, or (c) the study sample’s being treatment-naïve and therefore less vulnerable to potential tolerance effects of antidepressant medications (Fava & Offidani, 2011).”
Klein, D. N., Santiago, N. J., Vivian, D., Blalock, J. A., Kocsis, J. H., Markowitz, J. C., McCullough, J. P., Rush, A. J., Trivedi, M. H., Arnow, B. A., et al. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.4.681 · Cited by 138
Dunlop, B. W., Binder, E. B., Cubells, J. F., Goodman, M. M., Kelley, M. E., Kinkead, B., Kutner, M., Nemeroff, C. B., Newport, D. J., Owens, M. J., et al. (2012) · Trials · doi:10.1186/1745-6215-13-106 · Cited by 136
Self-citationKeller, M. B., Trivedi, M. H., Thase, M. E., Shelton, R. C., Kornstein, S. G., Nemeroff, C. B., Friedman, E. S., Gelenberg, A. J., Kocsis, J. H., Dunner, D. L., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0812 · Cited by 116
Self-citationBorges, S., Chen, Y.-F., Laughren, T. P., Temple, R., Patel, H. D., David, P. A., Mathis, M., Unger, E., Yang, P., & Khin, N. A. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08722 · Cited by 109
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Effects of anxiety on the long-term course of depressive disorders
Coryell, W., Fiedorowicz, J. G., Solomon, D., Leon, A. C., Rice, J. P., & Keller, M. B. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.081992 · Cited by 92
Bulloch, A., Williams, J., Lavorato, D., & Patten, S. (2014) · Depression and Anxiety · doi:10.1002/da.22173 · Cited by 45
Judd, L. L., Schettler, P. J., Rush, A. J., Coryell, W. H., Fiedorowicz, J. G., & Solomon, D. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m09918 · Cited by 40 · cited 3×
“Residual symptoms may predict relapse and recurrence because they indicate that patients are still suffering somewhat from the index depressive episode, making them more vulnerable to another depressive episode (Judd et al., 2016).”
Recovery and subsequent recurrence in patients with recurrent major depressive disorder
Dunlop, B. W., Holland, P., Bao, W., Ninan, P. T., & Keller, M. B. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.03.002 · Cited by 15
Self-citation
Cited by
Segal, Z. V., Dimidjian, S., Beck, A., Boggs, J. M., Vanderkruik, R., Metcalf, C. A., Gallop, R., Felder, J. N., & Levy, J. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4693 · Cited by 159
Okkersen, K., Jimenez-Moreno, C., Wenninger, S., Daidj, F., Glennon, J., Cumming, S., Littleford, R., Monckton, D. G., Lochmüller, H., Catt, M., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30203-5 · Cited by 123
Klein, N. S., Holtman, G. A., Bockting, C. L. H., Heymans, M. W., & Burger, H. (2018) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2018.06.006 · Cited by 29
Chen, H., He, Q., Wang, M., Wang, X., Pu, C., Li, S., & Li, M. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.027 · Cited by 27
Assessing in-session rumination and its effects on CBT for depression
Kennedy, J. C., Dunlop, B. W., Craighead, L. W., Nemeroff, C. B., Mayberg, H. S., & Craighead, W. E. (2022) · Behaviour Research and Therapy · doi:10.1016/j.brat.2022.104209 · Cited by 11
Self-citation
Metadata
- Authors
- Kennedy, J. C., Dunlop, B. W., Craighead, L. W., Nemeroff, C. B., Mayberg, H. S., & Craighead, W. E.
- Venue
- Journal of Consulting and Clinical Psychology
- Published
- 2018-02
- Volume
- 86
- Issue
- 2
- Pages
- 189-199
- ISSN
- 0022-006X (ISSN-L)
- 1939-2117
- OpenAlex
- W2784334732
- Cited by
- 17
- References
- 34
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.